Evaluation of the four mg warfarin initiation dose in patients with cardiovascular disease
DOI:
https://doi.org/10.46542/pe.2024.243.292297Keywords:
Efficacy, Initiation dose, Safety, WarfarinAbstract
Background: Warfarin is the most widely used oral anticoagulant for the prevention of stroke in patients with cardiovascular disease. In Indonesia, validation of the initiation dose of warfarin has never been carried out.
Objective: To evaluate the efficacy and safety of 4 mg warfarin initiation dose in achieving therapeutic targets.
Methods: It was a prospective observational study involving hospitalised and ambulatory patients administered a 4 mg warfarin initiation dose between days one and three. On day four, the INR was measured for three to seven days. Subsequently, the initiation dose was adjusted to the therapeutic INR. The INR level was measured every seven days until patients achieved therapeutic INR twice.
Results: A total of 14 patients were included in this study, with a mean age of 62 years. The most common indication for using warfarin was non-valvular atrial fibrillation (85.7%), with a CHA2DS2-VASc score between one and three and a HAS-BLED score ranging from zero to two. The median time to achieve therapeutic INR was 22.2 days, and the predictive value of the day four INR for determining the maintenance dose had an r2= 0.77.
Conclusions: The initiation dose of 4 mg warfarin effectively achieved therapeutic INR within an acceptable time.
References
Abdel-Aziz, M. I., Ali, M. A. S., Hassan, A. K. M., & Elfaham, T. H. (2015). Factors influencing warfarin response in hospitalized patients. Saudi Pharmaceutical Journal, 23(6), 642–649. https://doi.org/10.1016/j.jsps.2015.02.004
Ajimura, C. M., Jagan, N., Morrow, L. E., & Malesker, M. A. (2018). Drug interactions with oral inhaled medications. Journal of Pharmacy Technology, 34(6), 273–280. https://doi.org/10.1177/8755122518788809
Bader, L. A., & Elewa, H. (2016). The impact of genetic and non-genetic factors on warfarin dose prediction in MENA region: A systematic review. PLoS ONE, 11(12), 1–15. https://doi.org/10.1371/journal.pone.0168732
Baglin, T. P., Cousins, D., Keeling, D. M., Perry, D. J., & Watson, H. G. (2006). Safety indicators for inpatient and outpatient oral anticoagulant care: Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. British Journal of Haematology, 136(1), 26–29. https://doi.org/10.1111/j.1365-2141.2006.06379.x
Chang, T. Y., Liao, J. N., Chao, T. F., Vicera, J. J., Lin, C. Y., Tuan, T. C., Lin, Y. J., Chang, S. L., Lo, L. W., Hu, Y. F., Chung, F. P., & Chen, S. A. (2018). Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios. IJC Heart and Vasculature, 20, 56–62. https://doi.org/10.1016/j.ijcha.2018.08.003
Choi, K. H., Kim, A. J., Son, I. J., Kim, K.-H., Kim, K.-B., Ahn, H., & Lee, E. B. (2010). Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in a practical setting. Journal of Korean Medical Science, 25(3), 337–341. https://doi.org/10.3346/jkms.2010.25.3.337
Fisch, A. S., Perry, C. G., Stephens, S. H., Horenstein, R. B., & Shuldiner, A. R. (2013). Pharmacogenomics of anti-platelet and anti-coagulation therapy. Current Cardiology Reports, 15(7), 1–12. https://doi.org/10.1007/s11886-013-0381-3
Gage, B. F., Fihn, S. D., & White, R. H. (2000). Management and dosing of warfarin therapy. The American Journal of Medicine, 109(6), 481–488.
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., Abildstrøm, S. Z., Poulsen, H. E., Køber, L., & Torp-Pedersen, C. (2010). Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Archives of Internal Medicine, 170(16), 1433–1441. https://doi.org/10.1001/archinternmed.2010.271
Heneghan, C., Tyndel, S., Bankhead, C., Wan, Y., Keeling, D., Perera, R., & Ward, A. (2010). Optimal loading dose for the initiation of warfarin: A systematic review. BMC Cardiovascular Disorders, 10(1), 1–12. https://doi.org/10.1186/1471-2261-10-18
Ho, L. L., & Brighton, T. (2002). Warfarin, antiplatelet drugs and their interactions. Australian Prescriber, 25(4), 81–84. https://doi.org/https://doi.org/10.18773/austprescr.2002.073
Janardan, J., & Gibbs, H. (2018). Combining anticoagulation and antiplatelet drugs in coronary artery disease. Australian Prescriber, 41(4), 111. https://doi.org/10.18773/austprescr.2018.039
Kahlon, P., Nabi, S., Arshad, A., Jabbar, A., & Haythem, A. (2016). Warfarin dosing and time required to reach therapeutic international normalized ratio in patients with hypercoagulable conditions. Turkish Journal of Hematology, 33(4), 299. https://doi.org/10.4274/tjh.2015.0271
Kawai, M., Harada, M., Motoike, Y., Koshikawa, M., Ichikawa, T., Watanabe, E., & Ozaki, Y. (2019). Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: a prospective cohort study. IJC Heart & Vasculature, 22, 111–116. https://doi.org/10.1016/j.ijcha.2019.01.002
Lane, D. A., & Lip, G. Y. H. (2012). Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision-making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation, 126(7), 860–865. https://doi.org/10.1161/CIRCULATIONAHA.111.060061
Menditto, A., & Antonicelli, R. (2020). Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome? Journal of Geriatric Cardiology, 17(1), 51.
Momary, K. M., Saphiro, N. M., Viana, M., Nutescu, E. A., Helgason, C. M., & Cavalari, L. H., (2007). Factors influencing warfarin dose requirements in African–Americans. Pharmacogenomics, 8(11), 1535–154.
Richardson, C. L., Chapman, S., & White, S. (2021). Measuring the educational benefits of using a virtual patient to practice pharmacist-patient consultations. Pharmacy Education, 21, 382–389. https://doi.org/10.46542/pe.2021.211.382389
Sabry, S., Wakeel, L. M. E., Saleh, A., & Ahmed, M. A. (2022). Comparison of warfarin initiation at 3 mg versus 5 mg for anticoagulation of patients with mechanical mitral valve replacement surgery: A prospective randomized trial. Clinical Drug Investigation, 42(4), 309–318. https://doi.org/10.1007/s40261-022-01137-7
Siguret, V., Gouin, I., Debray, M., Perret-Guillaume, C., Boddaert, J., Mahé, I., Donval, V., Seux, M.-L., Romain-Pilotaz, M., Gisselbrecht, M., Verny, M., & Pautas, E. (2005). Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. The American Journal of Medicine, 118(2), 137–142.
Sridhar, V. S., Leung, P., Seymour, N., & Nagge, J. (2014). Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting. Canadian Family Physician, 60(11), 535–540.
Suriapranata, I. M., Tjong, W. Y., Wang, T., Utama, A., Raharjo, S. B., Yuniadi, Y., & Tai, S. S. W. (2011). Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Medical Genetics, 12(1), 1–9. https://doi.org/10.1186/1471-2350-12-80
